SVB Leerink analyst Mani Foroohar maintains Moderna (NASDAQ:MRNA) with a Underperform and raises the price target from $70 to $77.
SVB Leerink Maintains Underperform on Moderna, Raises Price Target to $77
SVB Leerink analyst Mani Foroohar maintains Moderna (NASDAQ:MRNA) with a Underperform and raises the price target from $70 to $77.
Related Posts
Capital One Downgrades Summit Hotel Properties to Equal-Weight, Lowers Price Target to $10
Capital One analyst Neil Malkin downgrades Summit Hotel Properties (NYSE:INN) from Overweight to Equal-Weight and lowers the price target from $14 to $10.
Digital Brands’ New Multi-Brand Website Registers Jump In Revenues, Average Order Value
Digital Brands Group Inc (NASDAQ:DBGI) said its new multi-brand website has seen a 462% increase in e-commerce revenue since…